|
Mechanismβ2-adrenergic receptor agonists |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.IT |
First Approval Date01 Nov 1994 |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date01 Jan 1988 |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseClinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Non-interventional study X-TRASafety and efficacy of safinamide (Xadago®) as add-on therapy to levodopa in mid- to late-stage Parkinson’s disease patients – a non-interventional observational study in daily practice of German neurologists - X-TRA
100 Clinical Results associated with Zambon GmbH
0 Patents (Medical) associated with Zambon GmbH
100 Deals associated with Zambon GmbH
100 Translational Medicine associated with Zambon GmbH